



Neuropathic Pain: Therapy and Mechanisms

Guest Editors:

Dr. Anand Rotte

Clinical and Regulatory Affairs,
Arcellx, Gaithersburg, MD, USA

Prof. Sam Eldabe

Honorary Professor, Warwick
University; Consultant, South
Tees Hospitals NHS Foundation
Trust, Middlesbrough, UK

Deadline for manuscript
submissions:

closed (31 July 2021)

Message from the Guest Editors

Neuropathic pain, known to be originating from abnormal or damaged nerves, often manifests as shooting or burning pain. It is especially burdensome when it turns chronic, negatively impacting the well-being of patients, their social relationships, daily activities, as well as work productivity. The use of opioids for the management of chronic pain has received significant attention in the recent decade, and several additional pharmacological and non-pharmacological treatments have been developed and approved for chronic pain management. This Special Issue on neuropathic pain intends to present the progress in the treatment of chronic pain and highlight the current understanding of pathophysiological and biochemical pathways involved in neuropathic pain. All article types related to neuropathic pain, pathophysiology, treatment (pharmacological as well as non-pharmacological), and biomarkers are considered within the scope of this Special Issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI